Praxis Precision Medicines to Participate in Upcoming Fireside Chat

Praxis Precision Medicines (NASDAQ: PRAX), a clinical-stage biopharmaceutical company focused on developing CNS disorder therapies, has announced an upcoming virtual fireside chat.

Rhea-AI Summary

Praxis Precision Medicines (NASDAQ: PRAX), a clinical-stage biopharmaceutical company focused on developing CNS disorder therapies, has announced an upcoming virtual fireside chat. CEO Marcio Souza will participate in a discussion with TD Cowen's Biotechnology Analyst Ritu Baral on September 2, 2025, at 10:00 AM EST.

The discussion will focus on Praxis' recent presentations at the 36th International Epilepsy Consortium (IEC). The company specializes in developing treatments for central nervous system disorders characterized by neuronal excitation-inhibition imbalance.

Argus Aug 29 session

-0.98% close to close Open Argus

Details

News Market Reaction – PRAX

On Aug 29, the day this news came out, PRAX closed 0.98% below the previous close.

Data tracked by StockTitan Argus for the Aug 29 session.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BOSTON, Aug. 29, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that CEO Marcio Souza will be participating a virtual fireside chat hosted by Ritu Baral, Biotechnology Analyst, TD Cowen on September 2, 2025 at 10:00amEST to discuss content shared by Praxis at the 36^th International Epilepsy Consortium (IEC).

The registration link for the fireside chat can be found here.

The overview of Praxis’ posters and presentation at the IEC event can be found here.

About Praxis  
Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across epilepsy and movement disorders, with four clinical-stage product candidates. For more information, please visit www.praxismedicines.com and follow us on Facebook, Instagram, LinkedIn and Twitter/X.

Investor Contact: 
Praxis Precision Medicines 
investors@praxismedicines.com 
857-702-9452 
 
Media Contact:
Dan Ferry
Life Science Advisors
Daniel@lifesciadvisors.com
617-430-7576

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When is Praxis Precision Medicines (PRAX) fireside chat scheduled for September 2025?

The virtual fireside chat is scheduled for September 2, 2025, at 10:00 AM EST, featuring CEO Marcio Souza in discussion with TD Cowen's Biotechnology Analyst Ritu Baral.

What will be discussed during the PRAX fireside chat with TD Cowen?

The fireside chat will discuss Praxis Precision Medicines' content and presentations shared at the 36th International Epilepsy Consortium (IEC).

Who is hosting the September 2025 fireside chat for Praxis Precision Medicines?

The virtual fireside chat is hosted by Ritu Baral, Biotechnology Analyst at TD Cowen.

What type of therapies is Praxis Precision Medicines (PRAX) developing?

Praxis is developing therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, based on genetic insights.